Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Champions Biotechnology Obtains BPU Patents

  • Champions Biotechnology obtained  patent rights encompassing two benzoylphenylurea (BPU) sulfur analog compounds that they report has shown potent activity against prostate and pancreatic cancer cell lines.

    BPU is an antimitotic inhibitor that targets microtubule-associated protein tau deficient tumors, a common feature of solid tumors. These inhibitors have performed better than Docetaxel (Taxotere) in direct-patient xenograft models of pancreatic cancer, according to the company.

    The company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »